Paul Rusilko, DO
Urology · Pittsburgh, PANPI 1164615936
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $57,288 of the $66,948 with a category attached, or 85.6%. Boston Scientific accounts for 98.4% of it on its own, with 7 other manufacturers making up the rest. 2025 is the largest year on record at $29,065, more than ten times the $1,668 reported in 2019. Among urology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 130 payments — averaging $514.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$66K
- Coloplast$387
- Teleflex LLC$238
- LSI Solutions Inc$130
- Baxter Healthcare$118
- Endo Pharmaceuticals Inc.$97
- plus $79 from 2 others
What the payments were for
- Speaking & faculty fees$57,28886%
- Travel & lodging$3,9366%
- Food & beverage$5,7239%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 118 | $65,900 |
| Coloplast | 4 | $387 |
| Teleflex LLC | 2 | $238 |
| LSI Solutions Inc | 1 | $130 |
| Baxter Healthcare | 1 | $118 |
| Endo Pharmaceuticals Inc. | 2 | $97 |
| Astellas Pharma US Inc | 1 | $64 |
| Axonics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMS 700$12,863
- AdVance XP$11,340
- GENERAL ERECTILE DYSFUNCTION$4,911
- AMS 800 Artificial Urinary Sphincter$4,881
- TACTRA$2,119
- AMS$881
- SpaceOAR System$820
- TITAN$303
- GENERAL MALE SUI$175
- GENERAL - THERAPIES$164
- UroLift$159
- JNW URTRAC$130
- ARTISS$118
How this compares
$66,948 in reported general payments places this provider in the 95th percentile of 596 urology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiaflexCollagenase Clostridium Hist. | 34 | $409,782 |
| MyrbetriqMirabegron | 141 | $67,129 |
| GemtesaVibegron | 35 | $19,682 |
| Mirabegron ErMirabegron | 33 | $12,996 |
| Tamsulosin Hcl | 232 | $2,941 |
| Trospium Chloride | 70 | $2,211 |
| Methenamine Hippurate | 30 | $1,422 |
| Oxybutynin Chloride ErOxybutynin Chloride | 39 | $877 |
| Oxybutynin Chloride | 22 | $345 |
| Finasteride | 30 | $214 |
| Cephalexin | 13 | $47 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Endo Pharmaceuticals Inc.Xiaflex | $97 | $409,78234 claims |
| Astellas Pharma US IncMyrbetriq | $64 | $67,129141 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 596 urology providers in Pennsylvania.
Other urology in Pittsburgh
- Quoc-Dien TrinhPittsburgh$111K
- Kiran SuryPittsburgh$61K
- Michelle SeminsPittsburgh$31K
- John AndersonBethlehem$2.1M
- Demetrius BagleyPhiladelphia$739K
- Paul SieberLancaster$631K
- Daniel EunPhiladelphia$226K
- Leonard GomellaPhiladelphia$190K
- Anthony DimatteoButler$189K
- Angelo BaccalaAllentown$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.